These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36303266)

  • 1. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
    Ferreira JP; Cleland JG; Girerd N; Bozec E; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; Solomon SD; Pitt B; Pfeffer MA; Shah AM; Petutschnigg J; Pieske B; Edelmann F; Zannad F
    Eur J Heart Fail; 2023 Jan; 25(1):108-113. PubMed ID: 36303266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial.
    Edelmann F; Gelbrich G; Duvinage A; Stahrenberg R; Behrens A; Prettin C; Kraigher-Krainer E; Schmidt AG; Düngen HD; Kamke W; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Wachter R; Pieske B
    Int J Cardiol; 2013 Nov; 169(6):408-17. PubMed ID: 24182675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
    Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
    JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
    Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA
    JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
    Ferreira JP; Cleland JG; Girerd N; Rossignol P; Pellicori P; Cosmi F; Mariottoni B; González A; Diez J; Solomon SD; Claggett B; Pfeffer MA; Pitt B; Petutschnigg J; Pieske B; Edelmann F; Zannad F
    Int J Cardiol; 2023 Apr; 377():86-88. PubMed ID: 36738846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
    Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Active and Passive Components of LV Diastolic Filling With Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: Mechanistic Insights From Spironolactone Response.
    Kosmala W; Przewlocka-Kosmala M; Marwick TH
    JACC Cardiovasc Imaging; 2019 May; 12(5):784-794. PubMed ID: 29248640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
    JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of spironolactone on diastolic function in haemodialysis patients.
    Hauser T; Dornberger V; Malzahn U; Grebe SJ; Liu D; Störk S; Nauck M; Friedrich N; Dörr M; Wanner C; Krane V; Hammer F; ;
    Int J Cardiovasc Imaging; 2021 Jun; 37(6):1927-1936. PubMed ID: 33544240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between long-term prescription of aldosterone antagonist and the progression of heart failure with preserved ejection fraction in hypertensive patients.
    Gu J; Fan YQ; Han ZH; Fan L; Bian L; Zhang HL; Xu ZJ; Yin ZF; Xie YS; Zhang JF; Wang CQ
    Int J Cardiol; 2016 Oct; 220():56-60. PubMed ID: 27372043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
    Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
    Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
    Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A machine learning-derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: Findings from the HOMAGE trial.
    Kobayashi M; Huttin O; Ferreira JP; Duarte K; González A; Heymans S; Verdonschot JAJ; Brunner-La Rocca HP; Pellicori P; Clark AL; Petutschnigg J; Edelmann F; Cleland JG; Rossignol P; Zannad F; Girerd N;
    Eur J Heart Fail; 2023 Aug; 25(8):1284-1289. PubMed ID: 37062878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial.
    Edelmann F; Holzendorf V; Wachter R; Nolte K; Schmidt AG; Kraigher-Krainer E; Duvinage A; Unkelbach I; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Stough WG; Pieske BM
    Eur J Heart Fail; 2015 Feb; 17(2):214-23. PubMed ID: 25418979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction.
    Kosmala W; Rojek A; Przewlocka-Kosmala M; Wright L; Mysiak A; Marwick TH
    J Am Coll Cardiol; 2016 Oct; 68(17):1823-1834. PubMed ID: 27765184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.